Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Merck & Co.

Share:
Related MRK
Cramer Looks At The Dow's Biggest Losers
The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease
Merck takes out Aussie biotech Viralytics for $394M (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Hold rating on Merck & Co. (NYSE: MRK), but lowered its price target from $49.00 to $47.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Merck & Co. closed on Tuesday at $43.34.

Latest Ratings for MRK

DateFirmActionFromTo
Feb 2018BMO CapitalMaintainsOutperformOutperform
Feb 2018Credit SuisseMaintainsOutperformOutperform
Feb 2018DZ BankUpgradesHoldBuy

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

View Comments and Join the Discussion!